Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.

Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A.

Cancer Res. 2002 Feb 1;62(3):840-7.

2.

FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.

Stadler CR, Knyazev P, Bange J, Ullrich A.

Cell Signal. 2006 Jun;18(6):783-94. Epub 2005 Aug 18.

PMID:
16109476
3.

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N.

J Clin Oncol. 2006 Aug 10;24(23):3747-55. Epub 2006 Jul 5.

PMID:
16822847
4.

The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.

da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP, Garicochea B.

Exp Mol Pathol. 2007 Feb;82(1):53-7. Epub 2006 Nov 3.

PMID:
17084840
5.

FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.

Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, Agresti R, Giovanazzi R, Pilotti S, Bertario L, Ravagnani F, Dragani TA.

Oncol Rep. 2005 Aug;14(2):415-9.

PMID:
16012724
6.
7.

The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.

Wang J, Stockton DW, Ittmann M.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6169-78.

8.

ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.

Choi KY, Rho YS, Kwon KH, Chung EJ, Kim JH, Park IS, Lee DJ.

Cancer Biomark. 2012-2013;12(3):115-24. doi: 10.3233/CBM-130299.

PMID:
23481570
9.

The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.

Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun MH, Fu H.

Ann Surg Oncol. 2010 Dec;17(12):3354-61. doi: 10.1245/s10434-010-1323-6. Epub 2010 Sep 16.

PMID:
20844967
10.

Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.

Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A, Shimizu K, Inoue H.

Cancer. 2003 Nov 15;98(10):2245-50.

11.

Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.

Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stättner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B.

Cancer Res. 2012 Nov 15;72(22):5767-77. doi: 10.1158/0008-5472.CAN-11-3654. Epub 2012 Sep 12.

12.

Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.

Sugiyama N, Varjosalo M, Meller P, Lohi J, Hyytiäinen M, Kilpinen S, Kallioniemi O, Ingvarsen S, Engelholm LH, Taipale J, Alitalo K, Keski-Oja J, Lehti K.

Cancer Res. 2010 Oct 15;70(20):7851-61. doi: 10.1158/0008-5472.CAN-10-1223. Epub 2010 Sep 28.

13.

FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.

Ho CK, Anwar S, Nanda J, Habib FK.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):94-6. doi: 10.1038/pcan.2009.49. Epub 2009 Nov 17.

PMID:
19918264
14.

G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.

Jézéquel P, Campion L, Joalland MP, Millour M, Dravet F, Classe JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G.

Br J Cancer. 2004 Jan 12;90(1):189-93.

15.

A single nucleotide change in the mouse genome accelerates breast cancer progression.

Seitzer N, Mayr T, Streit S, Ullrich A.

Cancer Res. 2010 Jan 15;70(2):802-12. doi: 10.1158/0008-5472.CAN-09-3239. Epub 2010 Jan 12.

16.

FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.

Xu W, Li Y, Wang X, Chen B, Wang Y, Liu S, Xu J, Zhao W, Wu J.

Eur J Cancer. 2010 Dec;46(18):3332-8. doi: 10.1016/j.ejca.2010.06.017. Epub 2010 Jul 16. Review.

PMID:
20638838
17.

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A.

J Hepatol. 2009 Jan;50(1):118-27. doi: 10.1016/j.jhep.2008.08.015. Epub 2008 Oct 12.

PMID:
19008009
18.
19.

Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.

Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA.

J Clin Oncol. 2005 Oct 10;23(29):7307-11. Epub 2005 Aug 1.

PMID:
16061909
20.

Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.

Bonafé M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C.

Clin Cancer Res. 2003 Oct 15;9(13):4860-4.

Supplemental Content

Support Center